Revolution Medicines, Inc. Investing Cash Flow
Revolution Medicines, Inc. (RVMD) reported Investing Cash Flow of -$1.49 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- Revolution Medicines, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$1.66B, a 4939.16% decline year-over-year.
- Revolution Medicines, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $172.62M.
- Revolution Medicines, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $74.88M.
- Revolution Medicines, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $24.85M.
- Revolution Medicines, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $118.06M.
- Revolution Medicines, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$554.39M.
- Revolution Medicines, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$342.60M.
- Revolution Medicines, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$24.12M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.66B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.49B 10-Q · filed 2026-08-05 | -$1.41B derived: sum of 3 quarters · filed 2026-08-05 | -$1.39B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $172.62M 10-Q · filed 2026-05-06 | $247.50M derived: sum of 2 quarters · filed 2026-05-06 | $272.35M derived: sum of 3 quarters · filed 2026-05-06 | $306.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $74.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $99.73M derived: sum of 2 quarters · filed 2026-02-25 | $134.01M derived: sum of 3 quarters · filed 2026-08-05 | $118.06M 10-K · filed 2026-02-25 |
| 2025-09-30 | $24.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $59.13M derived: sum of 2 quarters · filed 2026-08-05 | $43.18M 10-Q · filed 2025-11-05 | -$349.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $34.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $18.33M 10-Q · filed 2026-08-05 | -$374.58M derived: sum of 3 quarters · filed 2026-08-05 | -$396.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$15.95M 10-Q · filed 2026-05-06 | -$408.85M derived: sum of 2 quarters · filed 2026-05-06 | -$430.32M derived: sum of 3 quarters · filed 2026-05-06 | -$322.38M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$392.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$414.37M derived: sum of 2 quarters · filed 2026-02-25 | -$306.43M derived: sum of 3 quarters · filed 2026-02-25 | -$554.39M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$21.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $86.47M derived: sum of 2 quarters · filed 2025-11-05 | -$161.49M 10-Q · filed 2025-11-05 | -$541.89M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $107.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$140.02M 10-Q · filed 2025-08-06 | -$520.42M derived: sum of 3 quarters · filed 2026-02-25 | -$443.07M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$247.97M 10-Q · filed 2025-05-07 | -$628.37M derived: sum of 2 quarters · filed 2026-02-25 | -$551.02M derived: sum of 3 quarters · filed 2026-02-25 | -$594.56M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$380.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$303.05M derived: sum of 2 quarters · filed 2026-02-25 | -$346.59M derived: sum of 3 quarters · filed 2026-02-25 | -$342.60M 10-K · filed 2026-02-25 |
| 2023-09-30 | $77.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $33.81M derived: sum of 2 quarters · filed 2024-11-06 | $37.80M 10-Q · filed 2024-11-06 | $30.70M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$43.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$39.55M 10-Q · filed 2024-08-07 | -$46.65M derived: sum of 3 quarters · filed 2025-02-26 | -$170.09M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $4.00M 10-Q · filed 2024-05-08 | -$3.11M derived: sum of 2 quarters · filed 2025-02-26 | -$126.55M derived: sum of 3 quarters · filed 2025-02-26 | -$64.14M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$7.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$130.54M derived: sum of 2 quarters · filed 2025-02-26 | -$68.14M derived: sum of 3 quarters · filed 2025-02-26 | -$24.12M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$123.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$61.04M derived: sum of 2 quarters · filed 2023-11-06 | -$17.01M 10-Q · filed 2023-11-06 | -$8.48M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $62.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $106.43M 10-Q · filed 2023-08-08 | $114.96M derived: sum of 3 quarters · filed 2024-02-26 | $84.78M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $44.02M 10-Q · filed 2023-05-08 | $52.56M derived: sum of 2 quarters · filed 2024-02-26 | $22.38M derived: sum of 3 quarters · filed 2024-02-26 | -$100.40M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $8.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$21.64M derived: sum of 2 quarters · filed 2024-02-26 | -$144.43M derived: sum of 3 quarters · filed 2024-02-26 | -$142.12M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$30.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$152.96M derived: sum of 2 quarters · filed 2022-11-07 | -$150.65M 10-Q · filed 2022-11-07 | -$87.70M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$122.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$120.47M 10-Q · filed 2022-08-09 | -$57.53M derived: sum of 3 quarters · filed 2023-02-27 | -$158.49M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $2.31M 10-Q · filed 2022-05-09 | $65.25M derived: sum of 2 quarters · filed 2023-02-27 | -$35.71M derived: sum of 3 quarters · filed 2023-02-27 | -$172.21M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $62.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$38.02M derived: sum of 2 quarters · filed 2023-02-27 | -$174.52M derived: sum of 3 quarters · filed 2023-02-27 | -$234.23M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$100.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$237.46M derived: sum of 2 quarters · filed 2021-11-10 | -$297.18M 10-Q · filed 2021-11-10 | -$289.16M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$136.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$196.21M 10-Q · filed 2021-08-11 | -$188.19M derived: sum of 3 quarters · filed 2022-02-28 | -$247.99M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$59.72M 10-Q · filed 2021-05-10 | -$51.70M derived: sum of 2 quarters · filed 2022-02-28 | -$111.49M derived: sum of 3 quarters · filed 2022-02-28 | -$167.45M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $8.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$51.78M derived: sum of 2 quarters · filed 2022-02-28 | -$107.73M derived: sum of 3 quarters · filed 2022-02-28 | -$101.97M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$59.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$115.75M derived: sum of 2 quarters · filed 2020-11-12 | -$109.99M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$55.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$50.19M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $5.76M 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | -$1.34M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |